Rapid infusion of second dose rituximab appears safe
the ONA take:
Subsequent rituximab infusions can be safely administered over 60 minutes and without steroid premedication in an experienced outpatient infusion center as long as patients are appropriately screened, according to a new study published online ahead of print in the journal Supportive Care in Cancer.
For the study, researchers enrolled 50 patients with indolent and intermediate B-cell non-Hodgkin's lymphoma receiving rituximab treatment at The Ohio State Comprehensive Cancer Center-James Cancer Hospital in Columbus, Ohio.
All patients had received the first dose of rituximab according to the manufacturer-labeled standard titration schedule and had not experienced a grade 2 or higher infusion reaction. Participants then received the subsequent infusion without steroid premedication at 100 mg/hour over 15 minutes, with the remaining amount administered over 45 minutes.
Results showed that no infusion-related reactions occurred with the 60-minute rapid infusion protocol.
Researchers found that an average of about 94 minutes were saved with rapid infusion compared with the standard second dose infusion recommendation. Moreover, oncology nurses reported 100% satisfaction with the rapid infusion protocol.
The findings suggest that rapid infusions can reduce resource utilization and improve nursing satisfaction.
Subsequent rituximab infusions can be safely administered over 60 minutes and without steroid premedication.
Sign Up for Free e-newsletters
- Evolution of HER2-Positive Breast Cancer: Yesterday, Today, and Tomorrow
- Scalp Cooling With Dignicap May Reduce Alopecia During Chemotherapy for Breast Cancer
- Dedicated End-of-Life Education Program Improves Nurses' Care, Patient and Family Satisfaction
- Oncology Extended Care Clinic Reduced Urgent Cancer-Related ED Visits
- Reflexology, Aromatherapy May Reduce Pain, Anxiety of Brachytherapy for Cervical Cancer
- Hair Dyes and Cancer Risk (Fact Sheet)
- Taste Changes After Hematopoietic Stem Cell Transplant Affect QOL in Blood Cancers
- Hope, Optimism Reduce Psychological Distress in Advanced Cancer
- Mitomycin Extravasation Protocol
- Accurate Understanding of Capacity May Improve Workflow, Efficiency in Infusion Suite
- Nursing Practice Change Improved Chemo Administration, But Old Habits Die Hard
- Simple Adjustment Key to Paclitaxel Infusion Protocol That Reduced Hypersensitivity Reactions
- Online Program Aims to Assist With Clinical Trial Enrollment for Hematologic Cancers
- Education May Better Equip Nurses to Hold End-of-Life Conversations in Advanced Cancer
- Skipping the SICU Post Head and Neck Cancer Surgery May Improve Outcomes
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|